It Was Inevitable: FDA Inspection Delay Postpones BMS’s Liso-Cel Approval

Approval By Year-End Required For CVR Payout To Celgene Shareholders

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Bristol Myers Squibb confirmed that approval for lisocabtagene maraleucel (liso-cel) will be delayed by the US FDA’s COVID-19-related restrictions on travel for manufacturing facility inspectors.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Time is running out for BMS to win liso-cel approval by a crucial deadline for former Celgene shareholders • Source: Shutterstock

Bristol Myers Squibb Company confirmed on 16 November what many analysts and investors feared was inevitable – that the US Food and Drug Administration was not able to inspect the second of two manufacturing sites for lisocabtagene maraleucel (liso-cel) in time to inform an approval decision, putting in jeopardy a payout to Celgene Corporation shareholders tied to on-time approvals of three new products under the two companies’ merger agreement.

Analysts anticipated earlier this month that approval would be delayed after BMS executive vice president and chief medical officer Samit...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.